 |
Marshall
Space Flight Center
1999 Phase II
Improving
Crystal Quality to Enable the Development of New Drugs
BioSpace
International, Inc.
Huntsville, AL
|
INNOVATION
A major bottleneck for the
drug industry and research groups continues to be the inability to obtain
high-quality, diffractable crystals for structure determination in new
drug design. BioSpace International (BSI) has developed cutting-edge
technologies that can crystallize hard-to-crystallize proteins. Results
are repeatable and have been demonstrated in the laboratory and in space.
|
At left, a sharper, more uniform crystal is
grown in microgravity; right, a terrestrial
crystal grown under otherwise identical
circumstances is more diffuse and shows
a subgrain with a misorientation of 0.061º.
Optional Powerpoint
file
|
ACCOMPLISHMENTS
- First production run of eight
systems successfully used on STS-95 and STS-93.
- X-ray topography has demonstrated
the higher quality of space-grown crystals.
- Meetings with interested aerospace/drug
companies and federal laboratories are being scheduled.
|
COMMERCIALIZATION
- Product: New drugs
from the Dynamically Controlled Crystallization Systems (DCCS™),
which is operable in space and ground environments. The DCCS can
monitor, measure, and control the parameters that affect aggregation,
nucleation, and crystal growth. Size and quality of crystal can
be optimized accordingly.
- Service: Crystal growth
and x-ray diffractometry and topography analysis to improve crystal
quality. X-ray topography is used to measure crystal quality, determine
growth-induced defects, and provide a means of identifying corrective
actions.
- Unlike hanging/sitting
drop-diffusion technique hardware, the DCCS technology can be used
for protein crystal growth in Earth and space environments interchangeably,
with repeatable results.
- Patented in the U.S.:
Patent Cooperation Treaty for 55 countries worldwide.
- Primary market targets:Commercial
drug companies, National Institute of Health, National Cancer Institute,
and federal laboratories.
- BSI technologies will
be licensed to drug companies. Will also operate as a Contact Technical
Organization to crystallize proteins for drug companies/researchers.
Collaborations with peer-group companies and spinoffs are being
explored.
|
GOVERNMENT/SCIENCE
APPLICATIONS
- For NASA, efforts
will increase the understanding of the influence of gravity on macromolecules
and protein structure.
- For NIH and NIST,
supports the aims of the Human Genome Program by enabling structures
to be determined.
- Hard-to-crystallize
proteins have been provided by NIH and Brookhaven National Laboratories
to BSI for crystallization with the DCCS.
|
| For more
information about this firm, please send e-mail to company
representative
Return
to NASA SBIR Success Listings
|
Curator:
SBIR Support |